Poxel (OTCMKTS:PXXLF) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Poxel (OTCMKTS:PXXLF) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Poxel SA is a biopharmaceutical company. It offers drugs for metabolic diseases such as diabetes and related metabolic disorders. The company’s product pipeline consists of Imeglimin, PXL770 and PXL007 which are in clinical trial stage. Poxel SA is headquartered in Lyon, France. “

Separately, JMP Securities reaffirmed a buy rating and issued a $21.00 target price on shares of Poxel in a report on Friday, September 24th.

Shares of Poxel stock opened at $6.70 on Wednesday. The firm’s fifty day simple moving average is $6.70 and its 200-day simple moving average is $7.28. Poxel has a 12 month low of $6.47 and a 12 month high of $8.19.

About Poxel

Poxel SA, a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles.

Recommended Story: Dividend Kings

Get a free copy of the Zacks research report on Poxel (PXXLF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Poxel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poxel and related companies with MarketBeat.com's FREE daily email newsletter.